May 21, 2020
A New Jersey federal judge has given the preliminary green light to a $34 million deal between drug buyers and Bristol-Myers Squibb unit Celgene over allegations the drugmaker illegally monopolized a pair of cancer treatments.
April 07, 2020
Consumers, cities and union benefits are taking another shot at settling class action claims that Bristol-Myers Squibb's Celgene unit monopolized cancer drugs by proposing a pared down $34 million deal that excludes the class members whose opt outs spurred Celgene to scrap the original settlement.
January 08, 2020
Bristol-Myers Squibb's Celgene unit has dropped out of a $55 million deal that would have ended litigation alleging a sweeping scheme to monopolize the market for two cancer drugs that have racked up tens of billions of dollars in sales.
July 24, 2019
Celgene Corp. on Wednesday agreed to cut a check for $55 million to end a proposed class action alleging a sweeping scheme to monopolize the market for two cancer drugs that have racked up tens of billions of dollars in sales.
January 29, 2019
A proposed class of drug buyers accusing Celgene Corp. of creating a monopoly on two of its drugs shouldn't get a second crack at class certification, the biopharmaceutical company told a New Jersey federal court Monday.
November 01, 2018
A suit accusing biopharmaceutical firm Celgene Corp. of locking two competing generic drugs out of the market remains intact in New Jersey federal court, after a judge has refused to toss claims under state laws not currently at issue in the dispute.
October 30, 2018
A New Jersey federal judge Tuesday declined to certify a proposed consumer class in antitrust litigation accusing Celgene Corp. of creating a monopoly on two of its drugs, finding that the proposed class includes a large number of uninjured members.